ESMO Congress | Conference

Sacituzumab Govitecan Significantly Improves Survival in Metastatic TNBC

September 19th 2020

Treatment with sacituzumab govitecan led to a 59% reduction in the risk of disease progression or death compared with physician’s choice of single-agent chemotherapy in patients with previously treated metastatic triple-negative breast cancer.

Sacituzumab Govitecan Shows Sustained Activity in Heavily Pretreated Metastatic Urothelial Carcinoma

September 19th 2020

Sacituzumab govitecan-hziy continued to showcase significant activity with favorable tolerability in heavily pretreated patients with metastatic urothelial carcinoma who progressed on both platinum-based chemotherapy and checkpoint inhibition.

Spartalizumab/Dabrafenib Misses PFS End Point in Melanoma

September 19th 2020

Spartalizumab plus dabrafenib did not significantly improve progression-free survival over dabrafenib/trametinib in patients with untreated BRAF V600-mutant unresectable or metastatic melanoma.

Updated Data Demonstrate Continued PFS and OS Benefit With Ripretinib in Advanced GIST

September 19th 2020

The novel broad-spectrum KIT and PDGFRα inhibitor ripretinib continued to demonstrate clinically meaningful benefit as a fourth- or later-line treatment for patients with advanced gastrointestinal stromal tumors.

Higher PFS Rate Reported for Encorafenib/Binimetinib Combo Followed by Immunotherapy in Metastatic Melanoma

September 19th 2020

Early findings from a phase II efficacy and safety study may be the first step in developing a definitive rationale for sequencing targeted therapies and immunotherapies in patients with metastatic melanoma.

Urothelial Cancer Treatment Combination Fails To Meet OS End Points

September 19th 2020

Neither monotherapy with durvalumab or combination treatment with durvalumab plus tremelimumab met co-primary end points of overall survival vs chemotherapy for the treatment of metastatic urothelial cancer.

First-Line Pembrolizumab Improves Health-Related Quality of Life in DNA Repair-Deficient Metastatic Colorectal Cancer

September 19th 2020

As first-line therapy for patients with microsatellite instability-high and/or mismatch-repair deficient metastatic colorectal cancer, pembrolizumab improves quality of life compared with standard chemotherapy.

Nivolumab/Ipilimumab Combo Shows Durable Benefit at 4 Years in Advanced RCC

September 19th 2020

The benefits conferred by the combination of nivolumab and ipilimumab for the first-line treatment of advanced renal cell carcinoma remained durable after 4-year follow-up compared with treatment with sunitinib.

More Frequent Dosing of Lanreotide Autogel Delays the Use of More Toxic Treatments in Pancreatic, Midgut NETs

September 19th 2020

Improvements in disease-free survival and progression-free survival were observed in patients with progressive pancreatic or midgut neuroendocrine tumors whose frequency of dosing for lanreotide Autogel was increased from 120 mg every 28 days to every 14 days.

First-in-Human Study of RO7122290 Shows Promise in Patients With Select Solid Tumors

September 19th 2020

Safety and preliminary antitumor activity with the bispecific antibody RO7122290 alone or in combination with atezolizumab demonstrated preliminary antitumor activity and was safe for the treatment of patients with advanced solid tumors.

Balstilimab Monotherapy or Plus Zalifrelimab Active in Recurrent/Metastatic Cervical Cancer

September 19th 2020

The investigative PD-1 inhibitor balstilimab as a single agent and combined with the CTLA-4 inhibitor zalifrelimab showed promising objective response rates, regardless of PD-L1 expression, and a tolerable safety profile in patients with recurrent/metastatic cervical cancer.

PD-L1 Status Guides TIL activity in NeoTRIPaPDL1

September 19th 2020

Although atezolizumab did not improve pathological complete response when added to carboplatin and nab-paclitaxel, the immunotherapy increased the pCR by 10% or more in “immune-rich” groups with high-risk and locally advanced triple-negative breast cancer, and also turned PD-L1 negative tumors positive in most immunotherapy-treated patients.

Nivolumab/Cabozantinib Combo Doubles PFS in Frontline RCC

September 19th 2020

The combination of nivolumab and cabozantinib led to a 49% reduction in the risk of disease progression or death, while also significantly improving overall survival and doubling objective response rate, compared with sunitinib in the first-line treatment of patients with advanced renal cell carcinoma.

Neoadjuvant Durvalumab Induces Responses in Resectable NSCLC, But High Postsurgical Mortality Ends Study

September 19th 2020

Neoadjuvant durvalumab achieved a satisfactory complete surgical resection rate in patients with resectable non–small cell lung cancer, demonstrating preliminary promise for this treatment strategy.

Tumor Regression Is Observed With Neoadjuvant Atezolizumab in Resectable NSCLC

September 19th 2020

One preoperative injection of atezolizumab was considered safe and induced major pathological responses in select patients with resectable non–small cell lung cancer.

Updated Data Shows Xevinapant Significantly Improves OS in Locally Advanced Head and Neck Cancer

September 19th 2020

Three-year follow-up data for the phase 2 study of the first-in-class inhibitor of apoptosis protein antagonist, xevinapant, in combination with standard cisplatin-based concomitant fractionation chemoradiation therapy reduced the risk of mortality by half compared with CRT alone in patients with locally advanced squamous cell carcinoma of the head and neck.

Avelumab as Frontline Maintenance Improves OS Across Advanced Urothelial Carcinoma Subgroups

September 18th 2020

Frontline maintenance treatment with avelumab plus best supportive care improved both progression-free and overall survival compared with BSC alone across prespecified subgroups of patients with advanced or metastatic urothelial carcinoma that has not progressed on first-line platinum-based chemotherapy.

Despite Early Response, Frontline Avelumab Falls Short in Metastatic Urothelial Carcinoma

September 18th 2020

Despite observed responses, induction therapy with avelumab prior to standard of care gemcitabine/carboplatin fails to sustain clinically meaningful efficacy and is not an adequate strategy for the first-line treatment for patients with metastatic urothelial carcinoma.

Novel PD-1/PD-L1 Inhibitor Combo Promotes Antitumor Activity in Urothelial Carcinoma

September 18th 2020

The investigational PD-L1 inhibitor BGB-A333 in combination with the PD-1 inhibitor tislelizumab demonstrated marked antitumor activity, durable clinical responses, and a tolerable safety profile in patients with urothelial carcinoma.

Dr. Pothuri on Patient-Reported Outcomes With Niraparib in Advanced Ovarian Cancer

September 18th 2020

Bhavana Pothuri, MD, discusses patient-reported outcomes with niraparib in advanced ovarian cancer.